Vestmark Advisory Solutions Inc. raised its holdings in Astrazeneca Plc (NYSE:AZN – Free Report) by 135.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161,954 shares of the company’s stock after purchasing an additional 93,186 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Astrazeneca were worth $28,423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently bought and sold shares of AZN. Bank of Montreal Can grew its stake in Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after purchasing an additional 2,695,793 shares during the period. Holocene Advisors LP grew its stake in Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares during the period. Bank Julius Baer & Co. Ltd Zurich grew its stake in Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock valued at $317,107,000 after purchasing an additional 1,790,874 shares during the period. Raymond James Financial Inc. grew its stake in Astrazeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after purchasing an additional 1,487,662 shares during the period. Finally, Bank of America Corp DE grew its stake in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after purchasing an additional 1,461,786 shares during the period. Institutional investors own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
AZN has been the subject of a number of recent analyst reports. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Barclays upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings began coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Citigroup began coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.
Astrazeneca Price Performance
Shares of NYSE AZN opened at $189.88 on Friday. The firm has a market capitalization of $294.49 billion, a P/E ratio of 28.51, a P/E/G ratio of 1.54 and a beta of 0.26. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock’s 50-day simple moving average is $191.76 and its two-hundred day simple moving average is $182.72. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71.
Astrazeneca (NYSE:AZN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, equities analysts anticipate that Astrazeneca Plc will post 10.25 EPS for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
- Intuit’s Great SaaS Reset: Fired By AI
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
